Aducanumab and Its Effects on Tau Pathology: Is This the Turning Point of Amyloid Hypothesis?
Serena SilvestroAndrea ValeriEmanuela MazzonPublished in: International journal of molecular sciences (2022)
Alzheimer's disease (AD) is a neurodegenerative disorder affecting millions of people around the world. The two main pathological mechanisms underlying the disease are beta-amyloid (Aβ) plaques and intracellular neurofibrillary tangles (NFTs) of Tau proteins in the brain. Their reduction has been associated with slowing of cognitive decline and disease progression. Several antibodies aimed to target Aβ or Tau in order to represent hope for millions of patients, but only a small number managed to be selected to participate in clinical trials. Aducanumab is a monoclonal antibody recently approved by the Food and Drug Administration (FDA), which, targeting (Aβ) oligomers and fibrils, was able to reduce Aβ accumulation and slow the progression of cognitive impairment. It was also claimed to have an effect on the second hallmark of AD, decreasing the level of phospho-Tau evaluated in cerebrospinal fluid (CSF) and by positron emission tomography (PET). This evidence may represent a turning point in the development of AD-efficient drugs.
Keyphrases
- cerebrospinal fluid
- cognitive decline
- positron emission tomography
- drug administration
- computed tomography
- monoclonal antibody
- mild cognitive impairment
- clinical trial
- cognitive impairment
- end stage renal disease
- pet ct
- ejection fraction
- chronic kidney disease
- pet imaging
- newly diagnosed
- peritoneal dialysis
- multiple sclerosis
- brain injury
- blood brain barrier
- climate change
- drug delivery
- human health
- patient reported outcomes
- study protocol
- functional connectivity
- cerebral ischemia